Accelerating Decentralised Clinical Trials: Technology Imperatives...
Pharma Tech Outlook
Home ยป News

Accelerating Decentralised Clinical Trials: Technology Imperatives for CROs

Pharma Tech Outlook | Monday, May 08, 2023

The unprecedented global scenario due to COVID-19 has promptly accentuated decentralised clinical trials (DCTs) in medical research. Interestingly, public health concerns and travel restrictions helped contract research organisations (CROs) in fostering novel and transformative ideas in conducting clinical studies.

Decentralised clinical trials (DCTs) have become increasingly important in medical research as a result of the unique worldwide situation brought on by COVID-19. Interestingly, contract research organisations (CROs) were able to nurture innovative and game-changing concepts for carrying out clinical investigations because of public health concerns and travel restrictions. The CROs are constantly seeking ways to speed up data-driven insights through safe techniques and optimise research time. Here are some of the technological approaches that could help CROs perform decentralised clinical trials effectively and produce data-driven insights more quickly.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Decentralised clinical trials: A transformed way of clinical studies

Clinical trials that require sophisticated techniques, such as cell culture, bioanalytical research, or an MRI, must be carried out at a research facility. However, a drug or medication can be given locally in less complicated studies. In decentralised clinical trials, the subject (patient) receives medication at a nearby location while having their body vitals tracked and documented remotely or using wearable technology. Hybrid and decentralised studies can be performed at many locations, though not all are entirely virtual. A decentralised clinical trial is a novel approach that primarily focuses on the potency of its technology. The CROs should concentrate on creating a strong technological foundation. To maximise the potential of DCT, a secure and modern technology platform providing interoperability is necessary.

Building for the Future – A scalable, adaptive, and agile enterprise architecture

The reality of CROs includes electronic data collection, connected devices, and large-scale data processing. In contrast, CROs are also referred to as data firms. The connected devices will need to be able to store and process data locally due to the enormous rate at which data will be created. Therefore, these organisations' enterprise architecture needs to be flexible and scalable to accommodate all such future needs and trends.

Real-time, sophisticated data analytics are made possible by edge computing. Organisations must collaborate with numerous regional labs and sites to use DCTs. These facilities and venues may use many types of IT infrastructure. To meet these demands, organisations must invest in developing an agile corporate architecture. The following summarises some crucial technological and business architectural considerations:

• Revitalised Core: Modernising the core necessitates a horizontal, end-to-end strategy. A robust foundation at the backend is necessary for the success of new technologies used for real-time data processing, sophisticated analytics, ML, automation, low-code, hyperconnectivity, etc.

• Composable business architecture: There is a high demand for API-led system integrations with event-driven security built in.

• Governance framework: The breadth and complexity of IT governance are unavoidably broad in this environment. Modern monitoring and support solutions are needed since many IoT devices are dispersed around the globe, there are hyperconnected systems, and agile software development is used.

• Advanced analytics: Clinical research is fundamentally based on analytics. Predictive and exploratory analytics, data and text mining, and advanced data platforms with AI capabilities assist in generating meaningful results in real time and shorten the total research cycle.

‘Zero-trust’ Cyber Security

The governance of patient healthcare data is subject to tight rules set by federal authorities throughout the majority of the world. As a result, CROs are heavily responsible for data security. The enterprise architecture of the company is built for greater scalability, which comes with the inherent issue of managing more vulnerabilities. A secure-by-design policy for the organisation must be created by a committed and varied group of security professionals. It is crucial to have an integrated and complete approach to protecting the organisation's data.

Accomplishing Desired Results

Decentralised clinical trial models require a solid technological underpinning. These studies focus on the patient, are open to everyone, and increase testing variety. DCTs speed up the process of introducing fresh pharmaceuticals to the market. The technology used carefully can help to achieve desired outcomes.

When compared to conventional trials, the DCT model offers sponsors and patients several advantages. While sponsors may experience accelerated recruitment (in a market where competition for patients is growing), increased patient engagement and retention, a broader and more diverse patient population, time and cost savings, and seamless multisite management, patients benefit from convenience, reduced travel burden, and increased trial access. Before starting a DCT, it is important to think about who will support and manage the trial's technologies, whether any special protocol modifications are necessary to ensure compliance, who will manage source documents at decentralised sites, and what specifications will apply to any trial-specific procedures.

The majority of trials can benefit from virtualiSing one or more trial components, even if DCTs may not be appropriate for all trial designs. Sponsors are strongly urged to become familiar with the various DCT models available, including their benefits and drawbacks, before starting a DCT. In the end, the study protocol's structure and if HCP visits are required will determine which model is used.

Trials that utilise a mix of virtual approaches and in-person site visits are also options among the models. Since completely virtual trials are conducted off-site and utilise virtual means for all activities, including consent, they are more suitable for trials with simple visits and procedures. In contrast, DCTs that offer a combination of in-person visits to the clinical location or the patient's home for protocols that call for in-person interaction (such as when challenging treatments are required) are becoming more popular.

More in News

The drug development landscape is rapidly evolving as cutting-edge technologies and innovative approaches reshape how treatments are designed and delivered. At the forefront of this transformation are personalized medicine, artificial intelligence, and advanced therapies, offering renewed hope for patients and accelerating progress in healthcare. Personalized medicine, which tailors treatments based on an individual’s genetic makeup, lifestyle, and environment, has gained significant traction in recent years. Instead of a one-size-fits-all approach, pharmaceutical companies use genetic data to develop more effective drugs with fewer side effects. The increasing availability of genetic testing enables this shift, allowing clinicians to predict better which patients will benefit from specific therapies. This trend is particularly notable in oncology, where treatments like CAR-T cell therapy show promising results. Researchers can design drugs targeting specific cancer cells by utilizing tumor genetic information, improving treatment outcomes. Innovations Driven by Artificial Intelligence Artificial intelligence and machine learning are becoming game changers in drug development. These technologies help researchers examine extensive quantities of data more efficiently and accurately than conventional methods. AI can identify potential drug candidates, predict outcomes, and even suggest novel molecules for drug discovery. AI is also crucial in speeding up clinical trials. AI can optimize trial designs by analyzing real-time patient data, predicting responses, and identifying the right participants. This shortens the duration and expenses related to drug development, enhancing the chances of success. Regulatory agencies, like the U.S. Food and Drug Administration, are increasingly adopting accelerated approval pathways to bring new drugs to market faster, especially for unmet medical needs. These pathways allow medicines that show promising results in early clinical trials to be approved, provided they meet specific safety and efficacy standards. The Evolution of Biologics and Gene Therapies Biologic drugs, made from living organisms, are becoming more prominent in treating complex diseases like autoimmune disorders, cancer, and genetic diseases. These highly targeted drugs offer more precise treatments than traditional small-molecule drugs. Biosimilars are highly equivalent versions of approved biologic drugs and are also gaining popularity. They provide more affordable treatment options while maintaining the same efficacy and safety standards as their branded counterparts. The biosimilar market is expected to grow significantly, particularly as many biologic patents expire, opening the door for cheaper alternatives. Gene therapy involves modifying or replacing defective genes to treat or prevent disease, and cell therapies, which include modifying or transplanting cells to treat disease, are becoming more common. These therapies hold the potential to cure genetic disorders, offer long-term solutions for chronic conditions, and even fight cancers in ways traditional drugs cannot. ...Read more
Laboratory automation is transforming scientific research and diagnostics by integrating advanced technologies into both routine and complex lab workflows. Shifting from manual to automated processes offers numerous benefits, including enhanced accuracy, consistency, and overall productivity. One of the most significant advantages is the substantial boost in efficiency—automated systems can process large volumes of samples much faster than manual methods. Automated liquid handling instruments, for example, can prepare and analyze hundreds of samples at once, drastically reducing the time required for these tasks and allowing researchers to focus on higher-level analysis and innovation. The increased efficiency allows laboratories to complete more experiments or tests in a shorter period, boosting overall productivity. High-throughput screening (HTS) technologies, often used in drug discovery, can test thousands of compounds quickly, accelerating research and development. Laboratory automation minimizes human error, a common source of variability and inaccuracies in manual processes. Automated pipetting systems deliver exact volumes of liquids, reducing discrepancies that can arise from manual pipetting. Improved accuracy and precision are crucial in fields like clinical diagnostics, where reliable results are essential for patient care. Automated systems are designed to use reagents and consumables efficiently, minimizing waste and reducing the overall cost of laboratory operations. The efficiency is critical in high-volume testing environments like clinical laboratories and pharmaceutical research. Laboratory automation enhances safety by reducing the need for human intervention in potentially hazardous processes. Automated systems can handle dangerous chemicals, biological samples, and repetitive tasks, minimizing the risk of exposure to harmful substances and repetitive strain injuries. Laboratory staff can avoid repetitive motions that can lead to musculoskeletal disorders. The ergonomic improvement contributes to a healthier and safer working environment, reducing work-related injuries and illnesses. Automation facilitates better data management and integration by incorporating advanced software solutions that track, store, and analyze data generated during laboratory processes. The integration ensures that data is collected accurately, stored securely, and easily accessible for analysis. Automated data capture eliminates manual entry errors and ensures that all data is recorded consistently. Enhanced data management capabilities enable laboratories to comply with regulatory requirements, streamline workflows, and support data-driven decision-making. Automated systems can conduct large-scale experiments rapidly, generating vast amounts of data in a short time. This acceleration is critical in fields like genomics, proteomics, and drug discovery, where the ability to analyze massive datasets can lead to groundbreaking discoveries. Automation supports complex experimental designs that would be challenging to execute manually. Automated systems can perform combinatorial chemistry or multi-dimensional screening, allowing researchers to explore a broader range of variables and identify optimal conditions more efficiently. Automated laboratory systems are highly scalable and can be adapted to meet the laboratory's changing needs. Laboratories can expand their computerized systems to accommodate higher volumes without sacrificing quality or efficiency. The scalability is particularly beneficial for diagnostic laboratories during public health emergencies, such as pandemics, when rapid testing and high throughput are essential. Modern automated systems are designed with flexibility in mind. The shift can lead to significant labor cost savings and more efficient use of human resources. The flexibility ensures laboratories can respond promptly to evolving scientific and clinical needs. Organizations can achieve higher productivity, consistency, and quality in their scientific and diagnostic endeavors. ...Read more
Pharmaceutical companies increasingly rely on Contract Development and Manufacturing Organizations (CDMOs) to accelerate drug development, optimize manufacturing processes, and enhance overall operational efficiency. With their specialized expertise, advanced infrastructure, and strong regulatory compliance, CDMOs help reduce risks, improve profitability, shorten time to market, and leverage the latest technologies to support efficient drug development and commercialization. Key Functions of CDMOs Drug Formulation Development : CDMOs work with pharmaceutical companies to create and refine drug formulations that meet specific therapeutic and regulatory objectives. This process involves design, stability testing, and scale-up to ensure product consistency and efficacy. Analytical Testing and Quality Assurance : CDMOs conduct rigorous analytical testing throughout the development and manufacturing process to ensure product quality, safety, and compliance with regulatory standards. This includes method validation, stability testing, and release testing of APIs and finished dosage forms. Process Optimization and Scale-Up : CDMOs optimize manufacturing processes to enhance efficiency, reduce costs, and scale production from laboratory to commercial scale, involving process validation, technology transfer, and implementation of Good Manufacturing Practices (GMP). Regulatory Expertise and Compliance : CDMOs apply specialized knowledge of global regulatory requirements and guidelines governing pharmaceutical manufacturing. Caidya supports clinical development through regulatory expertise and technology-enabled services designed to help life sciences organizations manage complex development programs. CDMOs also assist pharmaceutical companies with regulatory approvals, submissions, audits and inspections, supporting compliance with applicable local and international standards. Supply Chain Management : CDMOs manage complex supply chains for raw materials, APIs, and packaging components, ensuring continuity of supply and minimizing risks associated with procurement and logistics. They optimize supply chain operations to support on-time delivery of pharmaceutical products to global markets. Alivia Health supports regulatory compliance and pharmaceutical operations through integrated healthcare services focused on coordinated patient care and treatment access. Benefits of Partnering with CDMO Services Accelerated Time to Market : CDMOs can expedite drug development timelines and market entry by streamlining formulation development, manufacturing scale-up, and regulatory submissions, enabling faster commercialization of new therapies. Cost Efficiency and Resource Optimization : CDMOs offer pharmaceutical companies the opportunity to outsource drug development and manufacturing, thereby optimizing resource allocation, reducing capital expenditures, offering flexible pricing models, and enhancing cost efficiency and financial predictability. Access to Specialized Expertise and Technologies : CDMOs, a group of skilled scientists, engineers, and regulatory experts, specialize in pharmaceutical development and manufacturing, offering access to advanced technologies, analytical capabilities, and specialized knowledge not available in-house. Risk Mitigation and Compliance Assurance : CDMOs maintain high-quality standards and regulatory requirements, reducing risks from manufacturing issues, non-compliance, and supply chain disruptions, instilling confidence in pharmaceutical companies and regulatory authorities. Flexibility and Scalability : CDMOs enable pharmaceutical companies to adjust production volumes based on market demand and lifecycle management needs, enhancing agility and operational efficiency by scalability in project management and manufacturing capacity. Choosing the Right CDMO Partner Selecting the proper Clinical Development Management Organization (CDMO) is crucial for outsourcing pharmaceutical development and manufacturing. Key factors include the CDMO's track record, industry reputation, capabilities, technological infrastructure, quality systems, compliance with GMP guidelines, and a collaborative approach that promotes open communication, transparency, and alignment with the company's strategic objectives and values. This ensures the best possible outcomes for the outsourcing process. ...Read more
Data analytics has emerged as a critical asset in the pharmaceutical industry, boosting productivity and supporting success across all stages of the production process. By leveraging data, companies can optimize operations, improve product quality, and shorten development timelines. Optimizing Clinical Trials Data analytics offers real-time insights into large databases, speeding up medication research and development. This helps identify potential drug candidates with greater precision, optimizing research efforts and reducing the time to market. Analytics in this area contribute to making treatments more accessible by lowering overall costs. Clinical trials are essential yet complex and expensive. Data analytics allows for the optimization of trial designs and recruitment processes. By analyzing clinical data, companies can monitor patient outcomes in real-time, predict adverse events, and improve drug safety and efficacy. This results in a more efficient drug development process while ensuring compliance with regulatory standards. Personalized Medicine and Predictive Maintenance and Equipment Reliability Analytics plays a critical role in enhancing patient outcomes by enabling more personalized and data-driven care strategies. Approaches associated with Astrid Pharma reflect the growing emphasis on leveraging patient data to tailor treatment plans effectively. By analyzing genetic profiles, medical histories, and lifestyle factors, pharmaceutical companies can design therapies that better align with individual needs. This personalized approach improves adherence to treatment regimens and contributes to better overall health outcomes, reinforcing a strong focus on patient-centric care. In pharmaceutical manufacturing, equipment reliability directly impacts product quality. Powered by data analytics, predictive maintenance allows manufacturers to monitor equipment health and predict when maintenance is required. This proactive strategy protects the consistency and caliber of output by reducing downtime and guaranteeing that machinery keeps running effectively. Mesa Labs provides solutions supporting pharmaceutical quality management, data analytics, and regulatory compliance. Product Quality and Compliance  Data analytics ensures that pharmaceutical manufacturing processes maintain high product quality and regulatory compliance. Real-time monitoring detects any deviations that might affect the integrity of the product. Anomalies are flagged, and immediate corrective actions are taken to maintain stringent quality standards required by regulatory bodies. Analytics-driven insights enhance manufacturing efficiency by identifying bottlenecks, optimizing resource allocation, and reducing waste. Companies can improve inventory management, forecast production needs, and streamline supply chains by analyzing production data. Significant cost reductions and operational enhancements follow, leading to improved resource use. ...Read more

Weekly Brief